Compare HRMY & LCID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | LCID |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2020 | 2020 |
| Metric | HRMY | LCID |
|---|---|---|
| Price | $35.34 | $6.30 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 7 |
| Target Price | ★ $44.11 | $15.71 |
| AVG Volume (30 Days) | 910.7K | ★ 25.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $868,453,000.00 | $595,271,000.00 |
| Revenue This Year | $19.75 | $71.67 |
| Revenue Next Year | $12.88 | $89.72 |
| P/E Ratio | $65.09 | ★ N/A |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $1.97 |
| 52 Week High | $40.87 | $25.22 |
| Indicator | HRMY | LCID |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 50.83 |
| Support Level | $35.05 | $5.59 |
| Resistance Level | $35.47 | $6.85 |
| Average True Range (ATR) | 1.59 | 0.90 |
| MACD | -0.20 | 0.06 |
| Stochastic Oscillator | 46.08 | 72.09 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design, which led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.